SE0201701D0 - Treatment of epithelial tumors and infections - Google Patents

Treatment of epithelial tumors and infections

Info

Publication number
SE0201701D0
SE0201701D0 SE0201701A SE0201701A SE0201701D0 SE 0201701 D0 SE0201701 D0 SE 0201701D0 SE 0201701 A SE0201701 A SE 0201701A SE 0201701 A SE0201701 A SE 0201701A SE 0201701 D0 SE0201701 D0 SE 0201701D0
Authority
SE
Sweden
Prior art keywords
treatment
specific
cell
protein
subunit
Prior art date
Application number
SE0201701A
Other languages
English (en)
Inventor
Ali M Harandi
Jan Holmgren
Original Assignee
Gotovax Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gotovax Ab filed Critical Gotovax Ab
Priority to SE0201701A priority Critical patent/SE0201701D0/sv
Publication of SE0201701D0 publication Critical patent/SE0201701D0/sv
Priority to CA2488366A priority patent/CA2488366C/en
Priority to AT03730976T priority patent/ATE418343T1/de
Priority to EP03730976A priority patent/EP1549340B1/en
Priority to PCT/SE2003/000935 priority patent/WO2003103708A1/en
Priority to US10/515,344 priority patent/US20100330101A1/en
Priority to DE60325492T priority patent/DE60325492D1/de
Priority to KR1020047019864A priority patent/KR101043341B1/ko
Priority to CN038186233A priority patent/CN1674935B/zh
Priority to AU2003241251A priority patent/AU2003241251B2/en
Priority to KR1020117007337A priority patent/KR20110042129A/ko
Priority to JP2004510827A priority patent/JP4937511B2/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
SE0201701A 2002-06-05 2002-06-05 Treatment of epithelial tumors and infections SE0201701D0 (sv)

Priority Applications (12)

Application Number Priority Date Filing Date Title
SE0201701A SE0201701D0 (sv) 2002-06-05 2002-06-05 Treatment of epithelial tumors and infections
JP2004510827A JP4937511B2 (ja) 2002-06-05 2003-06-05 免疫系を調節するための二官能性組成物およびその使用
PCT/SE2003/000935 WO2003103708A1 (en) 2002-06-05 2003-06-05 BIOFUNCTIONAL CpG OR OLIGO-/POLYNUCLEOTIDE AND TOXIN OR ENTEROTOXIN CONTAINING COMPOSITION
AT03730976T ATE418343T1 (de) 2002-06-05 2003-06-05 Biofunktionales cpg oder oligo-/polynucleotid und toxin oder enterotoxin enthaltende zusammensetzung
EP03730976A EP1549340B1 (en) 2002-06-05 2003-06-05 Biofunctional cpg or oligo-/polynucleotide and toxin or enterotoxin containing composition
CA2488366A CA2488366C (en) 2002-06-05 2003-06-05 Biofunctional cpg or oligo-/polynucleotide and toxin or enterotoxin containing composition
US10/515,344 US20100330101A1 (en) 2002-06-05 2003-06-05 BIFUNCTIONAL CpG OR OLIGO-/POLYNUCLEOTIDE AND TOXIN OR ENTEROTOXIN CONTAINING COMPOSITION
DE60325492T DE60325492D1 (de) 2002-06-05 2003-06-05 BIOFUNKTIONALES CpG ODER OLIGO-/POLYNUCLEOTID UND TOXIN ODER ENTEROTOXIN ENTHALTENDE ZUSAMMENSETZUNG
KR1020047019864A KR101043341B1 (ko) 2002-06-05 2003-06-05 생체 관능성 씨피지 또는 올리고-/폴리뉴클레오티드 및독소 또는 장독소 함유 조성물
CN038186233A CN1674935B (zh) 2002-06-05 2003-06-05 含有CpG或寡/多核苷酸以及毒素或肠毒素的双功能组合物
AU2003241251A AU2003241251B2 (en) 2002-06-05 2003-06-05 Biofunctional CpG or oligo-/polynucleotide and toxin or enterotoxin containing composition
KR1020117007337A KR20110042129A (ko) 2002-06-05 2003-06-05 생체 관능성 씨피지 또는 올리고-/폴리뉴클레오티드 및 독소 또는 장독소 함유 조성물

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0201701A SE0201701D0 (sv) 2002-06-05 2002-06-05 Treatment of epithelial tumors and infections

Publications (1)

Publication Number Publication Date
SE0201701D0 true SE0201701D0 (sv) 2002-06-05

Family

ID=20288076

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0201701A SE0201701D0 (sv) 2002-06-05 2002-06-05 Treatment of epithelial tumors and infections

Country Status (11)

Country Link
US (1) US20100330101A1 (sv)
EP (1) EP1549340B1 (sv)
JP (1) JP4937511B2 (sv)
KR (2) KR20110042129A (sv)
CN (1) CN1674935B (sv)
AT (1) ATE418343T1 (sv)
AU (1) AU2003241251B2 (sv)
CA (1) CA2488366C (sv)
DE (1) DE60325492D1 (sv)
SE (1) SE0201701D0 (sv)
WO (1) WO2003103708A1 (sv)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
PL1794174T3 (pl) 2004-09-01 2012-11-30 Dynavax Tech Corp Sposoby i kompozycje do hamowania wrodzonych odpowiedzi immunologicznych i autoodporności
AU2005316503A1 (en) * 2004-12-17 2006-06-22 Dynavax Technologies Corporation Methods and compositions for induction or promotion of immune tolerance
ES2544877T3 (es) * 2005-10-12 2015-09-04 Idera Pharmaceuticals Compuestos oligonucleótidos inmuno reguladores (IRO) para modular la respuesta inmune basada en receptor semejante a Toll
US8399423B2 (en) 2005-10-12 2013-03-19 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
US8383598B2 (en) 2005-10-12 2013-02-26 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
US8426375B2 (en) 2005-10-12 2013-04-23 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
US20100144845A1 (en) * 2006-08-04 2010-06-10 Massachusetts Institute Of Technology Oligonucleotide systems for targeted intracellular delivery
US8377898B2 (en) 2006-10-12 2013-02-19 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
EP2209896B1 (en) 2007-10-26 2017-03-01 Dynavax Technologies Corporation Methods and compositions for inhibition of immune responses and autoimmunity
ES2569907T3 (es) 2008-06-27 2016-05-13 Zoetis Services Llc Composiciones adyuvantes novedosas
EP3087988A3 (en) 2008-10-06 2017-03-01 Idera Pharmaceuticals, Inc. Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto
US8241608B2 (en) * 2010-03-23 2012-08-14 Development Center For Biotechnology Treating allergy with detoxified E. coli heat-labile enterotoxin
CN103153346A (zh) 2010-06-16 2013-06-12 戴纳瓦克斯技术公司 使用tlr7和/或tlr9抑制剂的治疗方法
AR091569A1 (es) * 2012-06-28 2015-02-11 Intervet Int Bv Receptores de tipo toll
KR20200039025A (ko) 2013-09-19 2020-04-14 조에티스 서비시즈 엘엘씨 유성 아쥬반트
CN104004698A (zh) * 2014-06-11 2014-08-27 河北科星药业有限公司 大肠埃希氏菌Escherichia coli及其制备方法
MX391930B (es) 2015-01-16 2025-03-21 Zoetis Services Llc Vacuna contra la fiebre aftosa.
CN117462701B (zh) * 2023-10-31 2026-04-07 暨南大学 一种靶向肝脏的变形红细胞制剂及其制备方法与应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4587044A (en) * 1983-09-01 1986-05-06 The Johns Hopkins University Linkage of proteins to nucleic acids
GB9317380D0 (en) * 1993-08-20 1993-10-06 Therexsys Ltd Transfection process
AU713040B2 (en) * 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
ES2264136T3 (es) * 1995-02-21 2006-12-16 Cantab Pharmaceuticals Research Limited Preparaciones virales, vectores, inmunogenos y sus vacunas.
US6261787B1 (en) * 1996-06-03 2001-07-17 Case Western Reserve University Bifunctional molecules for delivery of therapeutics
US6589940B1 (en) * 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
BR9909915A (pt) * 1998-04-09 2000-12-26 Smithkline Beecham Biolog Composições adjuvantes
DK1077722T3 (da) * 1998-05-22 2006-11-27 Ottawa Health Research Inst Fremgangsmåder og produkter til induktion af mukosaimmunitet
WO2001083528A2 (en) * 2000-05-01 2001-11-08 Powderject Vaccines, Inc. Nucleic acid immunization
WO2002011761A2 (en) * 2000-08-10 2002-02-14 Henry M. Jackson Foundation For The Advancement Of Military Medicine Vaccine against rsv

Also Published As

Publication number Publication date
KR20050027218A (ko) 2005-03-18
US20100330101A1 (en) 2010-12-30
JP4937511B2 (ja) 2012-05-23
DE60325492D1 (de) 2009-02-05
JP2005538957A (ja) 2005-12-22
CA2488366C (en) 2012-07-17
KR101043341B1 (ko) 2011-06-21
CN1674935B (zh) 2011-03-02
ATE418343T1 (de) 2009-01-15
WO2003103708A1 (en) 2003-12-18
EP1549340A1 (en) 2005-07-06
CA2488366A1 (en) 2003-12-18
KR20110042129A (ko) 2011-04-22
EP1549340B1 (en) 2008-12-24
AU2003241251A1 (en) 2003-12-22
CN1674935A (zh) 2005-09-28
AU2003241251B2 (en) 2008-07-24

Similar Documents

Publication Publication Date Title
ATE418343T1 (de) Biofunktionales cpg oder oligo-/polynucleotid und toxin oder enterotoxin enthaltende zusammensetzung
Cho et al. Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism
Eriksson et al. Cholera toxin and its B subunit promote dendritic cell vaccination with different influences on Th1 and Th2 development
NO20065366L (no) Antistoffer og molekyler som er avledet fra disse som binder til STEAP-1-proteiner
CY1107390T1 (el) Εμβολιο εναντι αντιγονων απο βακτηριδια
BR9812272A (pt) Respostas imunológicas contra antìgenos de hpv, eliciadas por composições que compreendem um antìgeno de hpv e uma proteìna de tensão ou um vetor de expressão capaz de expressar essas proteìnas
WO2001029233A3 (en) Chimeric immunogenic compositions and nucleic acids encoding them
Vordermeier et al. Immune responses induced in cattle by vaccination with a recombinant adenovirus expressing Mycobacterial antigen 85A and Mycobacterium bovis BCG
BRPI0413314A (pt) antìgeno quimérico para provocar uma resposta imune, métodos para realçar a apresentação de antìgeno em uma célula que apresenta antìgeno, para ativar uma célula que apresenta antìgeno, para provocar uma resposta imune, para quebrar a toleráncia, e para tratar uma condição imuno-tratável, composição farmacêutica, artigo de fabricação, método para produzir um antìgeno quimérico, polinucleotìdeo, microorganismo ou linhagem celular, e, vetor
CA2883000A1 (en) Bioconjugates comprising modified antigens and uses thereof
CY1117772T1 (el) Ληψη ειδικων κυτταρων tr1 αντιγονου τροφης ή αυτο-αντιγονου απο ενα πληθυσμο λευκοκυτταρων ή pbmc
ATE389712T1 (de) Krebs immuntherapie mit semi-allogenen zellen
PT1487485E (pt) Adjuvantes de imidazoquinolina para vacinas de adn
Gustafsson et al. Direct interaction between cholera toxin and dendritic cells is required for oral adjuvant activity
EA200900738A1 (ru) Слитые белки, содержащие антигены отторжения опухоли ny-eso-1 и lage-1
Zelenay et al. Immunostimulatory effects of plasmid DNA and synthetic oligodeoxynucleotides
NO20061203L (no) Fremgangsmate og sammensetning for rekontormering av multiepitopiske antigener for a initiere en immunrespons
Nyari et al. Vaccination of koalas (Phascolarctos cinereus) against Chlamydia pecorum using synthetic peptides derived from the major outer membrane protein
AU2003242535A1 (en) Improved polysaccharide and glycoconjugate vaccines
Rao et al. Modulation of host immune responses by overexpression of immunodominant antigens of Mycobacterium tuberculosis in bacille Calmette–Guerin
Yu et al. Three types of human C p G motifs differentially modulate and augment immunogenicity of nonviral and viral replicon DNA vaccines as built‐in adjuvants
CY1107845T1 (el) Γενετικα εμβολια με ανοσοενισχυτικο
JP2004503217A5 (sv)
CY1107952T1 (el) Δενδριτικα κυτταρα ενεργοποιημενα εν τη παρουσια γλυκοκορτικοειδων ορμονων ειναι ικανα να καταστελλουν αντιγονο-ειδικες αποκρισεις κυτταρων
NZ515041A (en) Nucleic acid immunization